Past history of hypersensitivity to the study drug;
Diagnosed diabetes;
Severe liver disease (including ALT or AST=2.5-fold the normal upper limit), biliary obstruction;
Ongoing treatment with cyclosporine within 2 weeks;
Renal dysfunction, including endogenous creatinine clearance male<120ml/min, female<105ml/min, serum creatinine=2mg/dl (186umol/L), Renal function progressive decline, GFR<30ml•min-1•1.73m-2;
Diagnosed or past history of ASCVD (including ACS, SCAD, revascularization, ICM, ischemic stroke, TIA, PASD, etc.
SBP=180mmHg, or DBP=110mmHg;
Ongoing treatment with Beta blockers, Diuretic;
Secondary hypertension, including SAS, PA, RAS, pheochromocytoma, Cushing's syndrome, aorta diseases, drug induced hypertension;
Ongoing treatment with statins, fibrates, and/or cation exchange resins within 2 weeks;
Pancreatic disease;
History of gastrectomy, short bowel syndrome;
Ongoing hormone replacement therapy;
Diagnosed or suspected malignant tumor;
Familial hypercholesterolemia;
Any diseases may limit the efficacy or safety of the study;
Pregnant or possibly pregnant woman, or breastfeeding woman, or woman who wishes to become pregnant during study participation;
IFG impaired fast glucose, FPG fasting plasma glucose, IGT impaired glucose tolerance, OGTT oral glucose tolerance test, PG plasma glucose, HbA1C hemoglobin A1C, LDL-C low-density lipoprotein cholesterol, TG triglycerides, SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST aspartate aminotransferase, GFR glomerular filtration rate, ASCVD arteriosclerotic cardiovascular disease, ACS acute coronary syndrome, SCAD stable coronary artery disease, ICM ischemic cardiomyopathy, TIA transient ischemic attack, PASD peripheral atherosclerotic disease, SAS sleep apnea syndrome, PA primary aldosteronism, RAS renal arterial stenosis

NCT03532620_exc_T1
Condition
hypersensitivity
NCT03532620_exc_T2
Drug
study drug
NCT03532620_exc_T3
Condition
diabetes
NCT03532620_exc_T4
Condition
liver disease
NCT03532620_exc_T5
Qualifier
Severe
NCT03532620_exc_T6
Measurement
AST
NCT03532620_exc_T7
Measurement
ALT
NCT03532620_exc_T8
Value
=2.5-fold the normal upper limit
NCT03532620_exc_T9
Condition
biliary obstruction
NCT03532620_exc_T10
Scope
ALT or AST
NCT03532620_exc_T11
Scope
Severe liver disease
NCT03532620_exc_T12
Drug
cyclosporine
NCT03532620_exc_T13
Procedure
treatment
NCT03532620_exc_T14
Temporal
Ongoing
NCT03532620_exc_T15
Temporal
within 2 weeks
NCT03532620_exc_T16
Condition
Renal dysfunction
NCT03532620_exc_T17
Measurement
endogenous creatinine clearance
NCT03532620_exc_T18
Person
male
NCT03532620_exc_T19
Person
female
NCT03532620_exc_T20
Value
<105ml/min
NCT03532620_exc_T21
Value
<120ml/min
NCT03532620_exc_T22
Measurement
serum creatinine
NCT03532620_exc_T23
Value
=2mg/dl
NCT03532620_exc_T24
Value
186umol/L
NCT03532620_exc_T25
Measurement
Renal function
NCT03532620_exc_T26
Value
progressive decline
NCT03532620_exc_T27
Measurement
GFR
NCT03532620_exc_T28
Value
<30ml•min-1•1.73m-2
NCT03532620_exc_T29
Scope
male<120ml/min, female<105ml/min
NCT03532620_exc_T30
Scope
endogenous creatinine clearance male<120ml/min, female<105ml/min, serum creatinine=2mg/dl (186umol/L), Renal function progressive decline, GFR<30ml•min-1•1.73m-2
NCT03532620_exc_T31
Condition
ASCVD
NCT03532620_exc_T32
Condition
ACS
NCT03532620_exc_T33
Condition
SCAD
NCT03532620_exc_T34
Procedure
revascularization
NCT03532620_exc_T35
Condition
ICM
NCT03532620_exc_T36
Condition
ischemic stroke
NCT03532620_exc_T37
Condition
TIA
NCT03532620_exc_T38
Condition
PASD
NCT03532620_exc_T39
Scope
ACS, SCAD, revascularization, ICM, ischemic stroke, TIA, PASD
NCT03532620_exc_T40
Measurement
SBP
NCT03532620_exc_T41
Measurement
DBP
NCT03532620_exc_T42
Value
=180mmHg
NCT03532620_exc_T43
Value
=110mmHg
NCT03532620_exc_T44
Drug
Beta blockers
NCT03532620_exc_T45
Temporal
Ongoing
NCT03532620_exc_T46
Procedure
treatment
NCT03532620_exc_T47
Drug
Diuretic
NCT03532620_exc_T48
Scope
Beta blockers, Diuretic
NCT03532620_exc_T49
Condition
Secondary hypertension
NCT03532620_exc_T50
Condition
SAS
NCT03532620_exc_T51
Condition
PA
NCT03532620_exc_T52
Condition
RAS
NCT03532620_exc_T53
Condition
pheochromocytoma
NCT03532620_exc_T54
Condition
Cushing's syndrome
NCT03532620_exc_T55
Condition
aorta diseases
NCT03532620_exc_T56
Condition
hypertension
NCT03532620_exc_T57
Qualifier
drug induced
NCT03532620_exc_T58
Scope
SAS, PA, RAS, pheochromocytoma, Cushing's syndrome, aorta diseases, drug induced hypertension
NCT03532620_exc_T59
Drug
statins
NCT03532620_exc_T60
Drug
fibrates
NCT03532620_exc_T61
Temporal
Ongoing
NCT03532620_exc_T62
Procedure
treatment
NCT03532620_exc_T63
Drug
cation exchange resins
NCT03532620_exc_T64
Temporal
within 2 weeks
NCT03532620_exc_T65
Scope
statins, fibrates, and/or cation exchange resins
NCT03532620_exc_T66
Condition
Pancreatic disease
NCT03532620_exc_T67
Procedure
gastrectomy
NCT03532620_exc_T68
Condition
short bowel syndrome
NCT03532620_exc_T69
Observation
History
NCT03532620_exc_T70
Scope
gastrectomy, short bowel syndrome
NCT03532620_exc_T71
Temporal
Ongoing
NCT03532620_exc_T72
Procedure
hormone replacement therapy
NCT03532620_exc_T73
Condition
malignant tumor
NCT03532620_exc_T74
Mood
suspected
NCT03532620_exc_T75
Mood
Diagnosed
NCT03532620_exc_T76
Scope
Diagnosed or suspected
NCT03532620_exc_T77
Condition
Familial hypercholesterolemia